Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 5,079 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 5,079 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total transaction of $845,805.87. Following the transaction, the chief executive officer owned 158,514 shares in the company, valued at approximately $26,397,336.42. This represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The shares were sold at an average price of $132.88, for a total transaction of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The shares were sold at an average price of $139.81, for a total transaction of $851,722.52.
• On Monday, July 21st, Steven Leonard Chapman sold 1,622 shares of Natera stock. The shares were sold at an average price of $139.29, for a total transaction of $225,928.38.
• On Tuesday, July 1st, Steven Leonard Chapman sold 5,343 shares of Natera stock. The shares were sold at an average price of $166.53, for a total value of $889,769.79.

Natera Stock Up 0.9%

Shares of NASDAQ:NTRA opened at $168.02 on Monday. Natera, Inc. has a twelve month low of $110.57 and a twelve month high of $183.00. The business has a 50 day moving average price of $154.35 and a 200 day moving average price of $153.68. The company has a market cap of $23.06 billion, a price-to-earnings ratio of -87.97 and a beta of 1.68.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The firm’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of a number of research analyst reports. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 price objective on the stock in a report on Monday, July 28th. Wall Street Zen cut Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Stephens restated an “overweight” rating and set a $183.00 target price on shares of Natera in a report on Friday, August 15th. Morgan Stanley restated an “overweight” rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Finally, Royal Bank Of Canada set a $268.00 target price on Natera and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company’s stock. Based on data from MarketBeat, Natera has an average rating of “Buy” and a consensus price target of $194.00.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of the business. LRI Investments LLC bought a new position in Natera during the 4th quarter worth about $29,000. Bank of Jackson Hole Trust bought a new stake in Natera in the 1st quarter valued at approximately $29,000. Rakuten Securities Inc. lifted its stake in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC bought a new stake in Natera in the 1st quarter valued at approximately $32,000. Finally, TCTC Holdings LLC lifted its stake in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 124 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.